Eleven Biotherapeutics major shareholder Jafco Super V3 Investment Limi Sells 2,600 Shares (EBIO)
Eleven Biotherapeutics (NASDAQ:EBIO) major shareholder Jafco Super V3 Investment Limi unloaded 2,600 shares of the company’s stock on the open market in a transaction dated Monday, August 18th. The shares were sold at an average price of $11.81, for a total transaction of $30,706.00. Following the transaction, the insider now directly owns 2,122,691 shares in the company, valued at approximately $25,068,981. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Eleven Biotherapeutics (NASDAQ:EBIO) opened at 11.41 on Thursday. Eleven Biotherapeutics has a 1-year low of $9.502 and a 1-year high of $19.333. The stock’s 50-day moving average is $11.94 and its 200-day moving average is $12.97. The company’s market cap is $175.6 million.
Eleven Biotherapeutics (NASDAQ:EBIO) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.47) by $0.04. Analysts expect that Eleven Biotherapeutics will post $-1.84 EPS for the current fiscal year.
Eleven Biotherapeutics, Inc, is a United States-based company, which develops protein-based biotherapeutics.
Receive News & Ratings for Eleven Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.